Grindr pays $250 million for PrEP provider Freddie: about $10,000 for each of its 25,000 active patients

Grindr agreed on Wednesday to buy PurposeMed, the parent of the HIV-prevention telehealth provider Freddie, for $250 million: $190 million in cash and $60 million in Grindr stock, according to the company's press release filed with the SEC. Up to $70 million more in cash is payable in 2028 if Freddie hits 2027 performance targets. It is Grindr's first major acquisition, and it is expected to close in the fourth quarter.

Grindr shares closed at $15.44 on Wednesday, down 4.2% from Tuesday's $16.12, and were at $15.51 in after-hours trading, according to Nasdaq. The company is worth about $2.68 billion, so the base price is roughly 9% of its market value, and about 12% with the full earnout.

The number behind the number: 25,000, not 55,000

The release and most coverage lead with Freddie having served "more than 55,000 patients" in Canada and the U.S. That is a cumulative count since 2020. The figure that matters for valuing the business is in Grindr's shareholder letter: as of the end of September, Freddie serves "over 25,000 active patients."

Run the deal against that and the price looks different:

Because Freddie guides to "more than" $80 million and $10 million, the true multiples are a little lower than shown. Still, 25 times EBITDA is a growth price, and Grindr is paying it for a business with an adjusted EBITDA margin of roughly 12.5% today.

What Grindr is betting on

The pitch rests on two company figures. Grindr says the combined U.S. telehealth and pharmacy model brings in more than $400 a month per active patient, or $4,800 a year for someone who stays in care all year. Chief executive George Arison told CNBC that 50,000 U.S. patients would mean roughly $240 million in annual revenue.

Today's revenue per active patient is well below that: $80 million across 25,000 patients works out to about $3,200 a year. The gap is mostly geography. The letter says the majority of Canadian revenue comes through pharmacy operations, while the higher U.S. figure depends on growing a U.S. base that Freddie only entered in 2024.

The audience is the asset Grindr brings. It says about 400,000 U.S. users list PrEP on their profiles and estimates more than 2 million more could benefit. Converting even a small share would dwarf Freddie's current base, which is why Grindr is willing to pay up front.

The fine print on margins

Grindr says the deal adds to adjusted EBITDA dollars but that U.S. build-out spending will weigh on margins at first. The letter labels a 40%-plus healthcare margin "at maturity" as illustrative and "not company guidance," and puts the expected adjusted EBITDA margin in the mid-teens for now. How much Grindr will spend on the build-out comes with third-quarter results in November.

The letter also notes that Freddie works with community health clinics in a federal drug pricing program that lets them buy eligible medicines at a discount and use insurance reimbursements to fund care. That makes the U.S. model sensitive to the rules of that program, a risk worth watching alongside patient growth. The Wall Street Journal also reported the deal.

More company news is in our stocks section.

Sources: Grindr press release (SEC); Grindr shareholder letter (SEC); CNBC; The Wall Street Journal; Nasdaq. Per-patient figures and multiples are our calculations from company figures. This is market information, not investment advice.